DBV Technologies SA (DBVT) - יחס רווח גולמי

סמלים רשמיים של חברת dbv-technologies.com (DBVT)

DBV Technologies S.A. (DBVT) is overcoming the aftermath of previous regulatory pauses while maintaining patient loyalty. The gross margin ratio on GURU.Markets demonstrates the current status of 0.00, visualizing operational viability. Ahead lies the creation of the Viaskin transdermal therapy ecosystem and the launch of unique patches, which will ensure a monopoly market capture with record growth in free cash flow.

שולי רווח גולמי: DBV Technologies SA (DBVT) עבור 04.07.2022 - 19.11.2026

פילוחים אנליטיים ודוחות נתונים של חברת DBV Technologies S.A. (DBVT)

- מחיר מניה ומחיר יעד קונצנזוס:
ניתוח בסיסי של החברה:DBVT dbv-technologies.com
מוצרים מיוצרים של DBV Technologies SA

A conservative approach to analyzing DBV Technologies S.A. (DBVT) requires evaluating direct production efficiency by calculating the difference between total revenue and production costs. By analyzing the gross sales margin, an investor determines the ability of this single-product biotech to generate profit, which is critical given the company's dependence on a single regulatory decision regarding the approval of its allergy patch.